By Fineline Cube 
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has entered into a licensing agreement with US-headquartered Caldera Therapeutics for its preclinical long-acting bispecific antibody (BsAb) QX030N, targeting autoimmune diseases. This strategic partnership underscores QYuns’ commitment to advancing innovative therapies in the autoimmune space.
Agreement Terms and Financials
Under the agreement, Caldera gains exclusive global rights to research, develop, regulate, manufacture, and commercialize QX030N. QYuns will receive an upfront payment of USD 10 million and a 24.88% equity stake in Caldera. Additionally, QYuns is eligible for milestone payments totaling up to USD 545 million, tied to clinical development, regulatory achievements, and commercial milestones, along with tiered royalties based on net sales.-Fineline Info & Tech